Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07192432 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
A Phase 1 study of HER2 Expressing Solid Tumors, sponsored by Vironexis Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT07192432 is a Phase 1 study of HER2 Expressing Solid Tumors that is actively recruiting participants, run by Vironexis Biotherapeutics. The registered enrollment target is 27 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07192432, a Phase 1 study of HER2 Expressing Solid Tumors, is actively recruiting participants, sponsored by Vironexis Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
Conditions Studied
Interventions
- GENETIC Dose Level 1, VNX-202
- GENETIC Dose Level 2, VNX-202
- GENETIC Dose Level 3, VNX-202
- GENETIC Dose Level 4, VNX-202
Study Locations (3)
California
- Valkyrie Clinical Trials - Los Angeles
Colorado
- SCRI Denver DDU at HealthOne - Denver
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2033-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07192432
The ClinicalTrials.gov registry entry for NCT07192432 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vironexis Biotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2 Expressing Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Dose Level 1, VNX-202 is the first listed.
NCT07192432 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07192432 about?
NCT07192432 is a clinical study titled "Gene Therapy for HER-Positive Cancer (SENTRY-HER2)". This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
What is the current status of trial NCT07192432?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2025-11-18. Estimated completion is 2033-10.
What conditions does trial NCT07192432 study?
This clinical trial studies the following conditions: HER2 Expressing Solid Tumors.
What interventions are being tested in trial NCT07192432?
The interventions under investigation include: Dose Level 1, VNX-202 (GENETIC), Dose Level 2, VNX-202 (GENETIC), Dose Level 3, VNX-202 (GENETIC), Dose Level 4, VNX-202 (GENETIC).
Who is sponsoring clinical trial NCT07192432?
This trial is sponsored by Vironexis Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07192432 being conducted?
This trial has 3 study locations across California, Colorado, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.